Preliminary results of the first vaccine to enter the human trial to prevent the outbreak of the new novel coronavirus have been impressive.
The US company Moderina launched the first experimental vaccine for corona virus, MRNA 1273, on humans in March, and now, about two months later, preliminary results have emerged.
The vaccine was administered to a few people in the first phase, and now the company says it has developed an immune response seen in patients who have recovered from code 19.
“The results of this provisional Phase 1 data are preliminary, but it shows that people who have been vaccinated have developed an immune response that helps them fight the virus,” said Ty Zax, the company’s chief medical officer.
“This data further strengthens our belief that MRNA 1273 has the ability to inhibit Main Code 19 and this capability will be further enhanced in new trials,” he added.
The company claims that the vaccine is safe and does not cause patients to experience redness or swelling of the skin.
Modrena’s CEO Stephen Benakl said in a conference call that preliminary results showed confidence that the vaccine would provide protection against the virus.
According to the company, tests on the vaccine in rats other than humans showed that it prevents the virus from replicating itself in the lungs.
The US government is spending about کروڑ 500 million on the vaccine, which is being developed by the company in partnership with the National Institute of Allergy and Infectious Diseases, headed by Dr. Anthony Fauchi.
In the first phase of the trial, people aged 18 to 55 were given three different doses of the vaccine, the full results of which have not yet been released.
The trial of the second phase of the vaccine was approved by the US Food and Administration this month and work will begin in the next few weeks.
In the second phase, researchers will look at its benefits and side effects in 600 people.
The third phase of the trial will be the largest and most important, working to prove the effectiveness of the vaccine, and will begin in July.
According to the company’s CEO, the research team’s focus is on launching the third phase as early as July.
Following the partial results of the first phase, the company also says that it is not researching higher doses because even lower doses are causing positive effects.
Millions of people will be hired for the third phase to determine if the vaccine is effective and does not cause any harm.
After the third phase, the FDA will decide to approve the use of this vaccine and this approval will be given only if it proves to be safe and effective while its benefits outweigh the risks.
The statement said more people would be protected from the virus than those from the lower castes.
It is believed that it usually takes many years to develop a vaccine, but due to the rapid spread of the coronavirus, the vaccine is being developed very fast.
Human trials of the vaccine are also underway in China, Britain and Germany, and China says it will test five vaccines on humans.
But it is not only a challenge to make the vaccine effective and safe, but also to provide billions of doses.
Several companies, including Modrina, have announced that they will begin mass production of the vaccine before all clinical trials are completed.
Moderina has announced a partnership with Lonza, a major pharmaceutical company, for this purpose, with the potential to produce one billion doses a year.
It should be noted that this vaccine uses a new technology that has not been used in any other approved vaccine so far.
Most conventional vaccines use a weakened or weakened version of the virus to train the body’s immune system to fight it, but this new vaccine uses a molecular messenger RNA that allows cells to make viral proteins on their own. Directs
MRNA directs cells to make spike proteins from the corona virus, which the virus uses to infect human cells.
The idea is that it will help the immune system identify spike proteins and make antibodies against them.
The technology is said to be a faster method of vaccine development and more stable than conventional vaccines